MCL Literature Feed

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

This large, real-world study demonstrates that any disease progression, even occurring more than 6 years after initial therapy, significantly worsens overall survival in mantle cell lymphoma.

This review describes the clinical presentation, diagnosis, and management of mantle cell lymphoma involving the gastrointestinal tract, a common site of extranodal disease requiring specific diagnostic consideration.

This German real-world study (2015-2020) reveals rising MCL incidence and poor outcomes, highlighting a dismal median OS of 3.0 months after cBTKi discontinuation, underscoring a critical unmet need.

A family history of hematological malignancy is associated with inferior event-free survival in mantle cell lymphoma, suggesting it may be a novel adverse prognostic factor.

This large epidemiological study identifies mantle cell lymphoma as one of the most frequent and aggressive nodal non-Hodgkin lymphoma subtypes in North Africa, highlighting regional disease patterns.

This large real-world study shows second primary malignancies in MCL patients double mortality risk versus non-MCL patients, mandating long-term surveillance for these subsequent cancers.

This retrospective study found one case of occult mantle cell lymphoma in 1328 adult tonsillectomies for benign indications, underscoring the value of routine histopathology for unexpected diagnoses.

This real-world study shows bendamustine-rituximab is the most common frontline therapy and BTK inhibitors for second-line, but median overall survival plummets in later lines, highlighting significant unmet need.

Mendelian randomization provides genetic evidence that obesity is a causal risk factor for developing mantle cell lymphoma, identifying a potentially modifiable risk factor for the disease.

This multi-center study provides real-world data on treatment outcomes for elderly mantle cell lymphoma patients, offering crucial insights for managing this common and clinically challenging population.

This real-world Colombian cohort confirms MIPI score as a key prognostic factor in MCL, where age-stratified frontline chemotherapy resulted in comparable responses despite different treatment intensities.

In a large low-grade lymphoma cohort, MCL histology was a key risk factor for lymphoma-related death, while secondary malignancies drove non-lymphoma mortality, underscoring diverse survival threats.

This real-world database analysis shows MCL patients treated at academic centers had significantly longer overall survival and higher trial participation, highlighting a major care disparity versus community settings.

Radiotherapy for localized orbital MCL achieves excellent long-term cancer-specific survival (83% at 15 years), supporting its use as a primary treatment, especially for elderly or frail patients.

A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.

This case report describes a rare presentation of primary thyroid MCL causing life-threatening airway compromise, emphasizing its inclusion in the differential diagnosis for rapidly enlarging neck masses.

This Danish nationwide study confirms blastoid morphology, high Ki67, and high CNS-IPI as key risk factors for secondary CNS lymphoma, supporting consideration of upfront CNS screening in high-risk patients.

This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.

A commentary on a 40-year retrospective analysis confirms that therapeutic advances have led to gradual but significant improvements in overall survival for mantle cell lymphoma patients.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

This paper describes the high frequency and characteristic patterns of gastrointestinal involvement in MCL, often as lymphomatous polyposis, highlighting the importance of endoscopy for accurate staging.

This retrospective series of six patients establishes that esophageal multiple lymphomatous polyposis in MCL signifies high tumor burden and a very poor prognosis, with median survival under two years.

This real-world study from Colombia confirms the prognostic value of the MIPI score and the survival benefit of autologous stem cell transplant in a Latin American MCL cohort.

This study validates a method using electronic health records to define real-world progression in MCL, providing a scalable endpoint that correlates strongly with overall survival for evidence generation.

In a prospective cohort of primary GI lymphomas including MCL, routine endoscopic surveillance significantly improved overall survival by detecting relapse early, supporting its role in post-treatment management.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.